{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:55:29Z","timestamp":1793346929152,"version":"4.5.0"},"reference-count":133,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec id=\"ab-drv230006-4\"><jats:title>Importance<\/jats:title><jats:p>Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis. Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use.<\/jats:p><\/jats:sec><jats:sec id=\"ab-drv230006-5\"><jats:title>Objective<\/jats:title><jats:p>To systematically review the validity of HRQL-focused PROMs used in patients with psoriasis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-drv230006-6\"><jats:title>Evidence Review<\/jats:title><jats:p>Using PubMed and Embase, full-text articles published in English or Spanish on development or validation studies for psoriasis-specific, dermatology-specific, or generic HRQL PROMs were included. Development studies included original development studies, even if not studied in psoriasis patients per Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations. If a study included multiple diagnoses, more than 50% of patients had to have psoriasis or psoriasis-specific subgroup analyses available. Data extraction and analysis followed the COSMIN guidelines. Two independent reviewers extracted and analyzed the data, including PROM characteristics, quality of measurement properties (structural validity, internal consistency, cross-cultural validity, reliability, measurement error, criterion validity, construct validity, and responsiveness), and level of evidence. PROMs were classified into 3 levels of recommendations: (1) PROM recommended for use; (2) PROM requires further validation; and (3) PROM not recommended for use.<\/jats:p><\/jats:sec><jats:sec id=\"ab-drv230006-7\"><jats:title>Findings<\/jats:title><jats:p>Overall, 97 articles were identified for extraction. This included 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs. According to COSMIN standards, most measures identified received a B recommendation for use, indicating their potential but requiring further validation. Only the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch) received an A recommendation for use given that it had sufficient content validity, structural validity, and internal consistency.<\/jats:p><\/jats:sec><jats:sec id=\"ab-drv230006-8\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This study identified a significant lack of information concerning the quality of HRQL measures in psoriasis. This gap in knowledge can be attributed to the fact that traditional measures were developed using validation criteria that differ from the current standards in use. Consequently, additional validation studies in accordance with contemporary standards will be useful in aiding researchers and clinicians in determining the most suitable measure for assessing HRQL in patients with psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.5439","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:01:08Z","timestamp":1706112068000},"page":"550","source":"Crossref","is-referenced-by-count":26,"title":["Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis"],"prefix":"10.1001","volume":"160","author":[{"given":"Lourdes M.","family":"P\u00e9rez-Chada","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary H.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak M. W.","family":"Balak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarem","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Creadore","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Villa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Woodbury","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mt Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Dermatology and Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor and Evidence-Based Practice Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"drv230006r1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0.","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"issue":"10","key":"drv230006r2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamadermatol.2018.1165","article-title":"Identifying a core domain set to assess psoriasis in clinical trials.","volume":"154","author":"Callis Duffin","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"drv230006r3","first-page":"243","article-title":"Measuring quality of life: apparent benefits, potential concerns.","volume":"4","author":"Till","year":"1994","journal-title":"Can J Oncol"},{"key":"drv230006r4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1741-7015-9-86","article-title":"Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science.","volume":"9","author":"McKenna","year":"2011","journal-title":"BMC Med"},{"issue":"1","key":"drv230006r5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. a conceptual model of patient outcomes.","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"issue":"Part 1","key":"drv230006r6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1348\/135910700168775","article-title":"Pathological worrying, illness perceptions and disease severity in patients with psoriasis.","volume":"5","author":"Fortune","year":"2000","journal-title":"Br J Health Psychol"},{"issue":"Pt 2","key":"drv230006r7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1348\/014466502163949","article-title":"Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia.","volume":"41","author":"Fortune","year":"2002","journal-title":"Br J Clin Psychol"},{"issue":"2","key":"drv230006r8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.det.2011.11.006","article-title":"Quality-of-life instruments: evaluation of the impact of psoriasis on patients.","volume":"30","author":"Heller","year":"2012","journal-title":"Dermatol Clin"},{"issue":"11","key":"drv230006r9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2165\/11591580-000000000-00000","article-title":"The burden of moderate to severe psoriasis: an overview.","volume":"30","author":"Raho","year":"2012","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"drv230006r10","first-page":"438","article-title":"Impact of psoriasis on quality of life: a qualitative study focused on patient perspectives.","volume":"19","author":"Schoenberg","year":"2021","journal-title":"Skinmed"},{"issue":"6","key":"drv230006r11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.6","article-title":"Effects of disease severity on quality of life in patients with psoriasis.","volume":"33","author":"Yavuz Daglioglu","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"drv230006r12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11136-008-9430-6","article-title":"The applications of PROs in clinical practice: what are they, do they work, and why?","volume":"18","author":"Greenhalgh","year":"2009","journal-title":"Qual Life Res"},{"key":"drv230006r13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41687-018-0061-6","article-title":"How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis.","volume":"2","author":"Greenhalgh","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"10","key":"drv230006r14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","article-title":"Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis.","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"drv230006r15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jaad.2019.09.008","article-title":"Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders.","volume":"88","author":"Perez-Chada","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"drv230006r16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.v34.11","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"drv230006r17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"drv230006r18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"drv230006r19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures.","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"issue":"5","key":"drv230006r20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","article-title":"COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures.","volume":"27","author":"Mokkink","year":"2018","journal-title":"Qual Life Res"},{"issue":"5","key":"drv230006r21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","article-title":"COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study.","volume":"27","author":"Terwee","year":"2018","journal-title":"Qual Life Res"},{"issue":"2","key":"drv230006r23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1023\/A:1026490117121","article-title":"Factor analysis, causal indicators and quality of life.","volume":"6","author":"Fayers","year":"1997","journal-title":"Qual Life Res"},{"issue":"1","key":"drv230006r24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11136-005-8290-6","article-title":"Two kinds of items in quality of life instruments: \u2018indicator and causal variables\u2019 in the EORTC qlq-c30.","volume":"15","author":"Boehmer","year":"2006","journal-title":"Qual Life Res"},{"key":"drv230006r25","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1111\/j.1524-4733.2004.7s105.x","article-title":"Development of needs-based quality of life instruments.","volume":"7","author":"McKenna","year":"2004","journal-title":"Value Health"},{"issue":"5","key":"drv230006r26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jdv.2018.32.issue-5","article-title":"A detailed analysis of \u2018not relevant\u2019 responses on the DLQI in psoriasis: potential biases in treatment decisions.","volume":"32","author":"Rencz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"drv230006r27","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s11136-022-03141-y","article-title":"A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis.","volume":"31","author":"Rencz","year":"2022","journal-title":"Qual Life Res"},{"issue":"8","key":"drv230006r28","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s11136-021-02803-7","article-title":"A Rasch model analysis of two interpretations of \u2018not relevant\u2019 responses on the Dermatology Life Quality Index (DLQI).","volume":"30","author":"Rencz","year":"2021","journal-title":"Qual Life Res"},{"issue":"2","key":"drv230006r29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1037\/0003-066X.33.2.138","article-title":"A research approach to improving our quality of life.","volume":"33","author":"Flanagan","year":"1978","journal-title":"Am Psychol"},{"issue":"4","key":"drv230006r30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/bjd.2012.166.issue-4","article-title":"Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.","volume":"166","author":"Norlin","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"drv230006r31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0022-3999(97)00036-6","article-title":"Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory.","volume":"42","author":"Fortune","year":"1997","journal-title":"J Psychosom Res"},{"issue":"5","key":"drv230006r32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00403-017-1743-2","article-title":"Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.","volume":"309","author":"Yfantopoulos","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"drv230006r33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11136-014-0630-y","article-title":"Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD.","volume":"24","author":"Twiss","year":"2015","journal-title":"Qual Life Res"},{"issue":"1","key":"drv230006r34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1590\/S0365-05962011000100005","article-title":"Comparison of quality of life questionnaires and their correlation with the clinical course of patients with psoriasis.","volume":"86","author":"Torres","year":"2011","journal-title":"An Bras Dermatol"},{"issue":"4","key":"drv230006r35","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bjd.2012.166.issue-4","article-title":"Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.","volume":"166","author":"Fernandez-Pe\u00f1as","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"drv230006r36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/jid.2011.238","article-title":"Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?","volume":"132","author":"Twiss","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"drv230006r37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000330560","article-title":"Characterization of patient-reported outcomes in moderate to severe psoriasis.","volume":"223","author":"Krenzer","year":"2011","journal-title":"Dermatology"},{"issue":"3","key":"drv230006r38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2340\/00015555-2833","article-title":"Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in patients with psoriasis treated with ustekinumab.","volume":"98","author":"Hesselvig","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"drv230006r39","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/sj.jid.5700875","article-title":"Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients.","volume":"127","author":"Nijsten","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"1","key":"drv230006r40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ced.1987.12.issue-1","article-title":"Psoriasis\u2013an index of disability.","volume":"12","author":"Finlay","year":"1987","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"drv230006r41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"drv230006r42","first-page":"202","article-title":"Dermatology quality of life scales\u2013a measure of the impact of skin diseases.","volume":"136","author":"Morgan","year":"1997","journal-title":"Br J Dermatol"},{"issue":"3","key":"drv230006r43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/ijd.2006.45.issue-3","article-title":"Developing a quality of life instrument in patients with psoriasis: the Psoriasis Quality of Life Questionnaire (PQLQ).","volume":"45","author":"Inanir","year":"2006","journal-title":"Int J Dermatol"},{"issue":"6","key":"drv230006r44","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s13555-020-00434-3","article-title":"Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis.","volume":"10","author":"Gottlieb","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"drv230006r45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jdv.2009.24.issue-1","article-title":"Development and validation of nail psoriasis quality of life scale (NPQ10).","volume":"24","author":"Ortonne","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"drv230006r46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12955-022-01970-6","article-title":"Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0).","volume":"20","author":"Liu","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"drv230006r47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jval.2013.10.003","article-title":"Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK.","volume":"16","author":"Swinburn","year":"2013","journal-title":"Value Health"},{"issue":"2","key":"drv230006r48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-2133.2003.05492.x","article-title":"Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.","volume":"149","author":"McKenna","year":"2003","journal-title":"Br J Dermatol"},{"issue":"6","key":"drv230006r49","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/ijd.2005.44.issue-6","article-title":"Development of the US PSORIQoL: a psoriasis-specific measure of quality of life.","volume":"44","author":"McKenna","year":"2005","journal-title":"Int J Dermatol"},{"issue":"8","key":"drv230006r50","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3417","article-title":"\u201cDLQI Seems to be \u2018Action\u2019, and Skindex-29 Seems to be \u2018Emotion\u2019\u201d: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures.","volume":"100","author":"Paudyal","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"drv230006r51","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/bjd.v182.5","article-title":"DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea.","volume":"182","author":"Rencz","year":"2020","journal-title":"Br J Dermatol"},{"issue":"34","key":"drv230006r52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007840","article-title":"Does the choice of tariff matter?: A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China.","volume":"96","author":"Zhao","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"drv230006r53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.2019.33.issue-1","article-title":"Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?","volume":"33","author":"Langenbruch","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"drv230006r54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2016.1219359","article-title":"EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.","volume":"20","author":"Pickard","year":"2017","journal-title":"J Med Econ"},{"issue":"5","key":"drv230006r55","first-page":"1151","article-title":"Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance.","volume":"315","author":"Hopkins","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"drv230006r56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000078581","article-title":"German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results.","volume":"209","author":"Augustin","year":"2004","journal-title":"Dermatology"},{"issue":"4-5","key":"drv230006r57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000012284","article-title":"Graphic representation of illness: a novel method of measuring patients\u2019 perceptions of the impact of illness.","volume":"67","author":"B\u00fcchi","year":"1998","journal-title":"Psychother Psychosom"},{"issue":"5","key":"drv230006r58","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11136-018-1819-2","article-title":"Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China.","volume":"27","author":"Liu","year":"2018","journal-title":"Qual Life Res"},{"issue":"3","key":"drv230006r59","first-page":"153","article-title":"Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey.","volume":"18","author":"Moradi","year":"2015","journal-title":"Arch Iran Med"},{"issue":"1","key":"drv230006r60","first-page":"37","article-title":"Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity.","volume":"151","author":"Chernyshov","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"drv230006r61","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/000155500300012873","article-title":"Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity.","volume":"80","author":"Lundberg","year":"2000","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"drv230006r62","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1365-2133.2005.07045.x","article-title":"How does psoriasis affect quality of life? Assessing an Ingram-regimen outpatient programme and validating the WHOQOL-100.","volume":"154","author":"Skevington","year":"2006","journal-title":"Br J Dermatol"},{"issue":"10","key":"drv230006r63","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jde.2013.40.issue-10","article-title":"Identification of psoriatic patients at risk of high quality of life impairment.","volume":"40","author":"Sojevic Timotijevic","year":"2013","journal-title":"J Dermatol"},{"issue":"8","key":"drv230006r64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.adengl.2013.02.008","article-title":"Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.","volume":"104","author":"Daud\u00e9n","year":"2013","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"drv230006r65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4103\/0378-6323.48689","article-title":"Impact of psoriasis on quality of life in Iran.","volume":"75","author":"Aghaei","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"drv230006r66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/CCID.S260323","article-title":"A method for designing a patient burden questionnaire in dermatology.","volume":"13","author":"Ezzedine","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"drv230006r67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"drv230006r68","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s11136-017-1699-x","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.","volume":"26","author":"Po\u00f3r","year":"2017","journal-title":"Qual Life Res"},{"issue":"3","key":"drv230006r69","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1046\/j.0022-202X.2003.09101.x","article-title":"Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis.","volume":"122","author":"Sampogna","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"4","key":"drv230006r70","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1046\/j.1365-2133.1999.03112.x","article-title":"Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI.","volume":"141","author":"Badia","year":"1999","journal-title":"Br J Dermatol"},{"issue":"7","key":"drv230006r71","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/ijd.2013.52.issue-7","article-title":"Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index.","volume":"52","author":"Khoudri","year":"2013","journal-title":"Int J Dermatol"},{"issue":"3","key":"drv230006r72","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bjd.12664","article-title":"Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes.","volume":"170","author":"Augustin","year":"2014","journal-title":"Br J Dermatol"},{"issue":"3","key":"drv230006r73","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4103\/0019-5154.82482","article-title":"Pasi and pqol-12 score in psoriasis: is there any correlation?","volume":"56","author":"Shankar","year":"2011","journal-title":"Indian J Dermatol"},{"issue":"7","key":"drv230006r74","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/archdermatol.2009.121","article-title":"Pictorial Representation of Illness and Self Measure (PRISM): a novel visual instrument to measure quality of life in dermatological inpatients.","volume":"145","author":"M\u00fchleisen","year":"2009","journal-title":"Arch Dermatol"},{"issue":"3","key":"drv230006r75","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","article-title":"Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.","volume":"14","author":"Koo","year":"1996","journal-title":"Dermatol Clin"},{"issue":"5","key":"drv230006r76","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/bjd.16927","article-title":"Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.","volume":"179","author":"Rencz","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"drv230006r77","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1684\/ejd.2018.3301","article-title":"PSOdisk is a reliable, intuitive instrument for the evaluation of psychological distress, which strongly correlates with DLQI: a preliminary study.","volume":"28","author":"Cozzani","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"9","key":"drv230006r78","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jdv.2012.26.issue-9","article-title":"Psodisk, a new visual method for assessing the burden of psoriasis on patients.","volume":"26","author":"Linder","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"drv230006r79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254882","article-title":"Psychometric characteristics of DLQI-BRA and Skindex-16 to measure the impact of dermatological diseases on quality of life in Brazilian patients.","volume":"16","author":"Meneguin","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"drv230006r80","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jdv.2012.27.issue-1","article-title":"Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.","volume":"27","author":"He","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"drv230006r81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1046\/j.1365-2133.2003.05378.x","article-title":"Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.","volume":"149","author":"Mazzotti","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"drv230006r82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/09546634.2011.631980","article-title":"Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.","volume":"24","author":"Safikhani","year":"2013","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"drv230006r83","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1365-2133.2001.04183.x","article-title":"Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.","volume":"144","author":"Touw","year":"2001","journal-title":"Br J Dermatol"},{"issue":"4","key":"drv230006r84","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/00015555-1731","article-title":"Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex.","volume":"94","author":"Sampogna","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"drv230006r85","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/nur.v12:6","article-title":"Quality of life of adults with chronic illness: a psychometric study.","volume":"12","author":"Burckhardt","year":"1989","journal-title":"Res Nurs Health"},{"issue":"4","key":"drv230006r86","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1365-2133.2005.07066.x","article-title":"Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis.","volume":"154","author":"Nijsten","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3","key":"drv230006r87","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000113150","article-title":"Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.","volume":"216","author":"Revicki","year":"2008","journal-title":"Dermatology"},{"key":"drv230006r88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1477-7525-10-37","article-title":"Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis.","volume":"10","author":"He","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"drv230006r89","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/jdv.2015.29.issue-4","article-title":"Results of the validation study of the Psodisk instrument, and determination of the cut-off scores for varying degrees of impairment.","volume":"29","author":"Sampogna","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"drv230006r90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/RHU.0000000000000630","article-title":"Routine Assessment of Patient Index Data 3 Score and Psoriasis Quality of Life assess complementary yet different aspects of patient-reported outcomes in psoriasis and psoriatic arthritis.","volume":"24","author":"Vakil-Gilani","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"drv230006r91","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archderm.138.6.803","article-title":"Scalpdex: a quality-of-life instrument for scalp dermatitis.","volume":"138","author":"Chen","year":"2002","journal-title":"Arch Dermatol"},{"issue":"8","key":"drv230006r92","first-page":"1011","article-title":"Shedding light on the \u201chidden psoriasis\u201d: a pilot study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire.","volume":"15","author":"Cohen","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"drv230006r93","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.","volume":"107","author":"Chren","year":"1996","journal-title":"J Invest Dermatol"},{"issue":"6","key":"drv230006r94","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.jid.5700212","article-title":"Testing and reducing skindex-29 using Rasch analysis: Skindex-17.","volume":"126","author":"Nijsten","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"4","key":"drv230006r95","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000069253","article-title":"The Development of a Disease-Specific Questionnaire to Assess Quality of Life for Psoriasis Patients: An Analysis of the Reliability, Validity, and Responsiveness of the Psoriasis Quality of Life Questionnaire.","volume":"3","author":"Koo","year":"2003","journal-title":"Dermatologie und Psychosomatik"},{"issue":"1","key":"drv230006r97","first-page":"101","article-title":"The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument.","volume":"158","author":"Evers","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3 Pt 1","key":"drv230006r98","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0190-9622(97)80214-9","article-title":"The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort.","volume":"36","author":"McKenna","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"drv230006r99","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/000155502320624078","article-title":"The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics.","volume":"82","author":"M\u00f8rk","year":"2002","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"drv230006r100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/02839319850162823","article-title":"The Norwegian version of the Quality of Life Scale (QOLS-N). A validation and reliability study in patients suffering from psoriasis.","volume":"12","author":"Wahl","year":"1998","journal-title":"Scand J Caring Sci"},{"issue":"5","key":"drv230006r101","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1046\/j.1524-4733.1999.25002.x","article-title":"The Norwegian version of the psoriasis disability index\u2013a validation and reliability study.","volume":"2","author":"Wahl","year":"1999","journal-title":"Value Health"},{"issue":"1","key":"drv230006r102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5114\/pdia.2014.40654","article-title":"The Polish version of Skindex-29: psychometric properties of an instrument to measure quality of life in dermatology.","volume":"31","author":"Janowski","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"issue":"5","key":"drv230006r103","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ced.1993.18.issue-5","article-title":"The Psoriasis Disability Index\u2013further analyses.","volume":"18","author":"Kent","year":"1993","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"drv230006r104","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2340\/0001555575240243","article-title":"The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress.","volume":"75","author":"Gupta","year":"1995","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"drv230006r105","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.0022-202X.2005.23775.x","article-title":"The psychometric properties of the psoriasis disability index in United States patients.","volume":"125","author":"Nijsten","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"4","key":"drv230006r106","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000107629","article-title":"The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients.","volume":"215","author":"Nijsten","year":"2007","journal-title":"Dermatology"},{"key":"drv230006r107","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"drv230006r108","first-page":"107","article-title":"Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system.","volume":"14","author":"Augustin","year":"2004","journal-title":"Eur J Dermatol"},{"issue":"1","key":"drv230006r109","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1477-7525-10-56","article-title":"Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire.","volume":"10","author":"Dauden","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"drv230006r110","doi-asserted-by":"publisher","first-page":"660","DOI":"10.2340\/00015555-1137","article-title":"Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: the QualiPso Questionnaire.","volume":"91","author":"Quintard","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"drv230006r111","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00403-021-02210-5","article-title":"Validation of psoriasis disability index (PDI) questionnaire Sinhala version.","volume":"314","author":"Liyanage","year":"2022","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"drv230006r112","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/bjd.1990.123.issue-6","article-title":"Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis.","volume":"123","author":"Finlay","year":"1990","journal-title":"Br J Dermatol"},{"issue":"10","key":"drv230006r113","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0001-7310(05)73154-9","article-title":"[Validation of the Spanish version of the Psoriasis Disability Index questionnaire in assessing the quality of life of patients with moderate-severe psoriasis].","volume":"96","author":"Vanaclocha","year":"2005","journal-title":"Actas Dermosifiliogr"},{"key":"drv230006r114","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1477-7525-1-53","article-title":"Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.","volume":"1","author":"Shikiar","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"drv230006r115","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1046\/j.1365-2133.2002.04613.x","article-title":"Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains.","volume":"146","author":"Schiffner","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"drv230006r116","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamadermatol.2019.4659","article-title":"Evaluation of the Frequency of \u201cNot Relevant\u201d Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis.","volume":"156","author":"Barbieri","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"drv230006r117","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/00015550510032832","article-title":"Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis.","volume":"85","author":"Mazzotti","year":"2005","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"drv230006r118","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s13555-021-00570-4","article-title":"Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY Phase 3 Trials.","volume":"11","author":"Warren","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7062","key":"drv230006r119","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/bmj.313.7062.919","article-title":"Postal questionnaire study of disability in the community associated with psoriasis.","volume":"313","author":"O\u2019Neill","year":"1996","journal-title":"BMJ"},{"issue":"1","key":"drv230006r120","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1684\/ejd.2014.2473","article-title":"Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.","volume":"25","author":"Chiricozzi","year":"2015","journal-title":"Eur J Dermatol"},{"issue":"12","key":"drv230006r121","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1111\/jdv.2015.29.issue-12","article-title":"Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis.","volume":"29","author":"Fotiou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"drv230006r122","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamadermatol.2018.5655","article-title":"Influence of \u201cnot relevant\u201d responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States.","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"7","key":"drv230006r123","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","article-title":"Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.","volume":"71","author":"Strand","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"drv230006r124","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3899\/jrheum.090373","article-title":"Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.","volume":"36","author":"Merkel","year":"2009","journal-title":"J Rheumatol"},{"issue":"10","key":"drv230006r125","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3899\/jrheum.161139","article-title":"OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"44","author":"Robson","year":"2017","journal-title":"J Rheumatol"},{"issue":"3","key":"drv230006r126","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1097\/00005650-198903001-00018","article-title":"Generic and disease-specific measures in assessing health status and quality of life.","volume":"27","author":"Patrick","year":"1989","journal-title":"Med Care"},{"issue":"8","key":"drv230006r127","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10.","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"drv230006r128","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1080\/13696998.2021.1948232","article-title":"COSMIN reviews: the need to consider measurement theory, modern measurement and a prospective rather than retrospective approach to evaluating patient-based measures.","volume":"24","author":"McKenna","year":"2021","journal-title":"J Med Econ"},{"issue":"1","key":"drv230006r129","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/13696998.2021.1907092","article-title":"Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?","volume":"24","author":"McKenna","year":"2021","journal-title":"J Med Econ"},{"issue":"1","key":"drv230006r130","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/13696998.2021.1948231","article-title":"Reply to the concerns raised by McKenna and Heaney about COSMIN.","volume":"24","author":"Mokkink","year":"2021","journal-title":"J Med Econ"},{"issue":"2","key":"drv230006r131","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: past, present and future.","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"drv230006r132","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life.","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"6","key":"drv230006r133","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"drv230006r22","first-page":"60","article-title":"Knowledge as a formative construct: a good alpha is not always better.","volume-title":"New Ideas in Psychology","author":"Stadler","year":"2021"},{"key":"drv230006r96","first-page":"41","volume-title":"the WHOQOL","author":"The Development of the World Health Organization Quality of Life Assessment Instrument","year":"1994"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2814261\/jamadermatology_prezchada_2024_rv_230006_1715717998.5705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:04:14Z","timestamp":1715785454000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2814261"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":133,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5439","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}